What Are the 22 Medical Conditions for Medical Marijuanas?

There is no single official list of 22 qualifying conditions for medical marijuana. The number “22” circulates because several U.S. states happen to list roughly that many conditions on their medical cannabis programs, but each state writes its own rules, and the totals range from fewer than a dozen to well over thirty. What most people searching for this list actually want is a clear picture of which health conditions are most commonly approved and which ones have real evidence behind them. The gap between those two categories is wider than you might expect.

Why There Is No Universal List

Medical marijuana is regulated state by state, not by a single federal agency. Each state legislature or health department decides which conditions qualify, and those lists have grown significantly over time. A 2025 comparison of state qualifying-condition lists found that by 2024, nearly all states with medical cannabis programs included at least one condition backed by strong evidence, but only about 8% of the individual conditions appearing across all state lists actually met the standard of substantial or conclusive evidence for effectiveness.¹ Of the 20 most commonly listed conditions across the country, only one, chronic pain, had substantial evidence supporting cannabis as an effective treatment. Seven of those top 20 were rated as either ineffective or lacking sufficient evidence.

The practical result is that qualifying conditions vary depending on where you live. In Colorado, the overwhelming majority of medical cannabis patients report chronic pain as their primary condition. In Connecticut, post-traumatic stress disorder dominates. States like Massachusetts and Maine see a mix of chronic pain, anxiety, and back and neck problems at the top.² These differences reflect legislative choices more than medical consensus.

The Conditions That Appear on Most State Lists

While individual states differ, the following conditions show up repeatedly across medical marijuana programs. Not all have equal evidence behind them, but this is the closest thing to a composite “list” that exists:

• Chronic pain: the single most common qualifying condition nationwide
• Cancer: including treatment-related symptoms like nausea and wasting
• Epilepsy and seizure disorders
• Multiple sclerosis
• HIV/AIDS: particularly for wasting and appetite loss
• Crohn’s disease and ulcerative colitis
• PTSD
• Glaucoma
• Amyotrophic lateral sclerosis (ALS)
• Parkinson’s disease
• Huntington’s disease
• Tourette syndrome
• Spinal cord injury or disease
• Neuropathy
• Cachexia or wasting syndrome
• Sickle cell disease
• Anxiety disorders
• Autism spectrum disorder
• Terminal illness
• Intractable nausea
• Chronic muscle spasms
• Severe or persistent pain unresponsive to other treatments

Some states also include conditions like fibromyalgia, migraines, traumatic brain injury, or an open-ended physician-discretion clause. That last category has become increasingly popular, with more states allowing doctors to recommend cannabis for any condition they judge appropriate.

Where the Evidence Is Strongest

The most comprehensive evaluation of cannabis as medicine came from a major 2017 report by the National Academies of Sciences, Engineering, and Medicine. That report reviewed thousands of studies and assigned evidence grades to various conditions. Only three therapeutic uses earned the top marks of “conclusive” or “substantial” evidence: treatment of chronic pain in adults, chemotherapy-induced nausea and vomiting, and spasticity associated with multiple sclerosis.³

Chronic Pain

Chronic pain is the runaway leader in medical cannabis use, and it is also the condition with the most supporting research. Cannabinoids interact with pain-processing pathways in the brain and spinal cord, and they have shown particular promise against inflammatory and nerve-related pain that resists conventional treatment.⁴ For neuropathic pain specifically, a systematic review of 14 randomized controlled trials found that cannabis-based treatments produced a statistically meaningful reduction in pain scores, along with improvements in sleep and quality of life.⁵ A Cochrane review found that cannabis-based medicines roughly doubled the proportion of patients achieving moderate pain relief compared with a placebo, though the absolute numbers were modest: about 39% of cannabis patients reported at least a 30% reduction in pain, compared with 33% on placebo.⁶

That gap might not sound dramatic, and it is worth being honest about it. Cannabis is not a miracle painkiller. But for people living with neuropathic pain who have already tried standard medications without relief, even a modest improvement can make a meaningful difference in daily life.

Chemotherapy-Induced Nausea and Vomiting

The FDA has approved synthetic cannabinoid drugs like dronabinol and nabilone specifically for nausea and vomiting caused by chemotherapy, making this one of the oldest and most established medical uses. Research supports the idea that cannabinoids are safe and useful for managing these side effects, along with cancer-related pain.⁷ Many patients find cannabinoids particularly helpful when standard anti-nausea drugs have failed or produce intolerable side effects of their own.

Multiple Sclerosis Spasticity

Muscle spasticity in MS, the tightness and involuntary spasms that can make movement painful, responds relatively well to cannabis-based treatments. A Cochrane review found that nabiximols (an oromucosal spray containing both THC and CBD) roughly doubled the odds of patients reporting a meaningful reduction in spasticity compared with a placebo.⁸ In a real-world review of MS patients using medical cannabis, about 72% reported pain improvement, 48% reported spasticity relief, and 40% reported better sleep.⁹ Both oral cannabinoids and oromucosal sprays appear effective for pain and spasticity, while evidence for other MS symptoms like bladder dysfunction or tremor remains thin.¹⁰

Conditions With Promising but Incomplete Evidence

Several qualifying conditions fall into a middle ground where early results look encouraging but the research base is not yet strong enough to draw firm conclusions.

Epilepsy

The FDA approval of cannabidiol (Epidiolex) for certain severe forms of childhood epilepsy was a landmark moment for medical cannabis. For treatment-resistant epilepsy more broadly, an observational study of children and adolescents treated with CBD-enriched cannabis found that over half experienced at least a 50% reduction in monthly seizure frequency. Younger patients and those receiving higher CBD doses tended to respond better, though close to half of participants reported adverse reactions, which were the main reason some stopped treatment.¹¹ The evidence is encouraging enough that epilepsy appears on nearly every state’s qualifying list, but the best results seem concentrated in specific, severe syndromes rather than all seizure disorders.

Tourette Syndrome

Tics in Tourette syndrome may respond to cannabis-based treatments. A randomized trial found that patients receiving THC and CBD experienced a significantly greater reduction in tic scores over six weeks compared to those receiving placebo.¹² A meta-analysis confirmed the finding, showing a significant reduction in both tic severity scores and premonitory urge scores, though the effect on obsessive-compulsive symptoms, which frequently accompany Tourette, did not reach statistical significance.¹³

Anxiety and PTSD

Anxiety disorders and PTSD are among the fastest-growing qualifying conditions across states, but the evidence is mixed and dose-dependent. Data from the UK Medical Cannabis Registry showed that patients treated for generalized anxiety disorder experienced significant improvements in anxiety scores and quality of life over six months.¹⁴ But the National Academies report classified the evidence for anxiety and PTSD as limited or insufficient.³ One complicating factor: while low doses of CBD may ease anxiety, higher doses of THC can trigger or worsen it. The relationship between cannabis and psychiatric conditions is genuinely complicated, and blanket recommendations are hard to make responsibly.

Sleep Disorders

Many people use cannabis to help with sleep, and secondary sleep improvements show up frequently in trials focused on pain or spasticity. A small trial found that THC significantly reduced the time it took participants to fall asleep compared with placebo.¹⁵ The National Academies rated the evidence for sleep as moderate, but primarily when sleep problems were secondary to another condition like chronic pain, not for standalone insomnia.

Conditions Where the Evidence Is Weak Despite Common Listing

Glaucoma

Glaucoma is one of the most frequently cited qualifying conditions and one of the most poorly supported. Cannabis does lower eye pressure, which is the target of glaucoma treatment. But the pressure-lowering effect lasts only a few hours, meaning a patient would need to dose multiple times throughout the day and night. That frequency of use brings significant side effects, cognitive impairment, and the risk of dependence, all without clear evidence that it actually prevents vision loss any better than standard eye drops.^{16 17} Most ophthalmologists consider cannabis an inappropriate treatment for glaucoma. Its persistence on qualifying-condition lists is a relic of early cannabis legalization arguments from the 1970s and 1980s rather than a reflection of current medical thinking.

Cachexia and Wasting

Wasting syndrome, or cachexia, is listed in many state programs, particularly for HIV/AIDS and cancer patients. The logic is intuitive: cannabis stimulates appetite, so it should help people who are dangerously underweight. But a systematic review and meta-analysis found that low-quality evidence showed no significant benefits from cannabinoids for weight gain, appetite stimulation, or quality of life in cancer-related cachexia.¹⁸ Cannabis might make people feel hungrier, but translating that into meaningful weight restoration in seriously ill patients has not panned out in rigorous studies.

Sickle Cell Disease

Sickle cell disease causes episodes of severe pain, and cannabis has been proposed as a treatment. A randomized clinical trial testing inhaled cannabis against placebo in adults with sickle cell disease found no statistically significant difference in pain ratings over five days of treatment. There was a modest improvement in mood interference, but the overall pain relief did not differ meaningfully from placebo.¹⁹ The trial was small, and more research is underway, but the existing data is not encouraging.

Neurodegenerative Conditions on State Lists

Parkinson’s disease, ALS, and Huntington’s disease appear on many state lists, driven by patient advocacy and the lack of effective treatments for these devastating conditions. For Parkinson’s disease, an open-label observational study found significant improvements in tremor, rigidity, and slowness of movement after cannabis use, as measured by standard clinical scales.²⁰ That is promising on the surface, but open-label studies (where everyone knows they are receiving the active treatment) tend to overestimate benefits because of the placebo effect, and this study was small.

For ALS, patients who have used cannabis report benefits for both motor symptoms like rigidity and cramps and non-motor symptoms like pain, sleep quality, and mood, with only minor side effects such as drowsiness or dry mouth.²¹ These are patient-reported outcomes from surveys, not controlled trials, so the evidence is preliminary. But given that ALS has very few treatment options and is ultimately fatal, the bar for symptom management may reasonably be lower than for other conditions.

Autism Spectrum Disorder

Autism is one of the more recently added qualifying conditions, and it is still only found in a handful of state programs. The research that does exist comes mostly from observational studies and retrospective analyses rather than large controlled trials. A systematic review found that cannabis products reduced the intensity of symptoms like hyperactivity, self-harm, anxiety, irritability, and aggression in some patients, with improvements also seen in social interaction and attention.²² An analysis of 188 patients treated with CBD-rich cannabis oil found that after six months, roughly 84% reported at least some improvement, and specific symptoms like restlessness and rage attacks improved in over 90% of cases.²³ CBD-rich formulations appear to be tolerated relatively well, though the long-term safety remains unknown.²⁴ The evidence is early-stage and encouraging in a cautious way. Controlled trials are needed before firm conclusions are possible.

Skin Conditions Are the New Frontier

A less publicized area of research involves inflammatory skin diseases. The skin has its own endocannabinoid system, and early studies suggest cannabis-based topical products may help manage conditions like atopic dermatitis, psoriasis, and contact dermatitis. These products are generally well tolerated when applied to the skin.²⁵ Dermatological conditions do not yet appear on most state qualifying lists, but this is an area where the science is advancing faster than the legislation.

The Opioid Reduction Question

One of the most politically influential arguments for medical cannabis is that it might help people reduce their use of opioid painkillers. A retrospective survey found that medical cannabis patients reported a 64% decrease in opioid use, along with fewer medication side effects and improved quality of life.²⁶ A systematic review and meta-analysis offered a more cautious picture: for people with chronic non-cancer pain, adding medical cannabis was associated with a modest reduction in daily opioid dose, but for cancer-related pain, no meaningful reduction was found.²⁷

Not all data points in the same direction. A retrospective analysis of patients over time found that those authorized for medical cannabis actually had higher average daily opioid doses than those without, and the gap did not narrow over the study period.²⁸ This could reflect the fact that patients who seek medical cannabis are often those with the most difficult-to-treat pain, meaning they were already on higher opioid doses before starting cannabis. The relationship between cannabis access and opioid use is real but more tangled than advocacy messaging often suggests.

Drug Interactions and Safety

If you are using medical cannabis alongside other medications, drug interactions are a genuine concern. Both THC and CBD are processed by the same liver enzymes that metabolize a wide range of common drugs. This means cannabis can raise or lower the blood levels of other medications in unpredictable ways, potentially making them either less effective or more toxic.²⁹ Older adults and people with liver or kidney disease are at higher risk, and anyone using blood thinners, anti-seizure medications, or immunosuppressants should discuss cannabis use with their doctor.³⁰ Cannabinoids are generally well tolerated on their own, but “well tolerated” does not mean “can be freely combined with everything.”

Pediatric Use Is a Different Calculation

Several qualifying conditions, especially epilepsy and autism, involve children. Pediatric use of medical cannabis carries distinct considerations. The developing brain is sensitive to cannabinoids, and there is a potential for long-term neurodevelopmental effects that remain poorly understood. The same drug interaction concerns that apply to adults are amplified in children, who may be taking multiple medications for complex conditions.³¹ Most pediatric cannabis research focuses on CBD-dominant formulations rather than THC-heavy products, which is an important distinction. The risk-benefit equation for a child with hundreds of seizures per month looks very different from the equation for an adult managing moderate pain.

How States Decide What Makes the List

State qualifying-condition lists are shaped by a mix of scientific evidence, patient advocacy, physician lobbying, and political negotiation. The result is often a list that includes some well-supported conditions alongside others where the science is thin. Some states have responded to this mismatch by moving toward open-ended physician-discretion models, where any condition a licensed doctor considers appropriate can qualify. Others have added petitioning processes, allowing patients or advocacy groups to request that new conditions be added.

The trend since 2017 has been toward broader access. States have added conditions like anxiety, autism, and chronic pain that were not on early lists, and several have loosened the definition of existing conditions. The gap between what is legally approved and what is scientifically supported has widened along the way.¹ That does not necessarily mean states are being reckless. In many cases, the legal framework is running ahead of clinical trials because the federal classification of cannabis as a Schedule I substance has historically made research difficult. States are, in effect, betting that the evidence will eventually catch up. Whether that bet pays off depends on conditions that are as much political as they are medical.